Drug Trial Radar · NCT03115112
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Last checked: Nov 20, 2026Latest source record: Jun 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
386
Actual
Start
Oct 12, 2017
Primary completion
Oct 31, 2018
Study completion Oct 31, 2018
Sponsor
- Lead sponsor
- TheracosIndustry
- Sponsor type
- Industry
- First posted
- Apr 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Conditions
- Type 2 Diabetes Mellitus
Interventions
BexagliflozinDrug
tablets containing 20 mg bexagliflozin
SitagliptinDrug
tablets containing 100 mg sitagliptin
Placebo for sitagliptinDrug
inactive tablets to match the appearance of sitagliptin tablets
Placebo for bexagliflozinDrug
inactive tablets to match the appearance of bexagliflozin tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c From Baseline to Week 24Time frame: Baseline to week 24
Locations
56 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Research Site 1357
Lincoln, California
Clinical Research Site 1358
Long Beach, California
Clinical Research Site 1361
San Dimas, California
Clinical Research Site 1031
Port Orange, Florida
Clinical Research Site 1271
Chicago, Illinois
Clinical Research Site 1359
Topeka, Kansas
Clinical Research Site 1009
Berlin, New Jersey
Clinical Research Site 1037
Trenton, New Jersey
Clinical Research Site 1008
Munroe Falls, Ohio
Clinical Research Site 1360
San Antonio, Texas
Clinical Research Site 3119
Hodonín, Czechia
Clinical Research Site 3123
Mladá Boleslav, Czechia
Clinical Research Site 3120
Olomouc, Czechia
Clinical Research Site 3112
Prague, Czechia
Clinical Research Site 3122
Prostějov, Czechia
Clinical Research Site 9102
Balatonfüred, Hungary
Clinical Research Site 9101
Balatongyörök, Hungary
Clinical Research Site 9106
Budapest, Hungary
Clinical Research Site 9107
Szeged, Hungary
Clinical Research Site 9105
Zalaegerszeg, Hungary
Clinical Research Site 9103
Zamárdi, Hungary
Clinical Research Site 6031
Chiba, Japan
Clinical Research Site 6037
Chiba, Japan
Clinical Research Site 6042
Chiba, Japan
Clinical Research Site 6040
Fukuoka, Japan
Clinical Research Site 6035
Fukuoka, Japan
Clinical Research Site 6034
Ibaraki, Japan
Clinical Research Site 6039
Ibaraki, Japan
Clinical Research Site 6041
Ibaraki, Japan
Clinical Research Site 6032
Ibaraki, Japan
Clinical Research Site 6033
Ōsaka, Japan
Clinical Research Site 6036
Shizuoka, Japan
Clinical Research Site 6038
Tochigi, Japan
Clinical Research Site 7137
Gdansk, Poland
Clinical Research Site 7144
Krakow, Poland
Clinical Research Site 7142
Krakow, Poland
Clinical Research Site 7139
Krakow, Poland
Clinical Research Site 7141
Krakow, Poland
Clinical Research Site 7120
Lublin, Poland
Clinical Research Site 7138
Lublin, Poland
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.